Shares in ReNeuron, the life sciences firm that is using Glasgow’s Southern General Hospital for the world’s first stem clinical cell trial for a stroke treatment, leapt this morning after it reported that patients were showing signs of improvement with no side effects.
The group will provide a detailed update on its first nine patients to doctors and scientists at the 22nd European Stroke Conference taking place in London this week.
In an update to the market this morning, it said: “There were no cell-related or immunological adverse events reported in any of the patients treated.
“Sustained reductions in neurological impairment and spasticity were observed in most patients compared with their stable pre-treatment baseline performance.”
Shares in the company jumped more than 20 per cent in early trading.